Segmentation of key figures (Details 7) - USD ($)
$ in Millions |
3 Months Ended |
6 Months Ended |
Jun. 30, 2020 |
Jun. 30, 2019 |
Jun. 30, 2020 |
Jun. 30, 2019 |
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 11,347
|
$ 11,764
|
$ 23,630
|
$ 22,870
|
| Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(4.00%)
|
|
3.00%
|
|
| Net sales, change in %, cc |
(1.00%)
|
|
6.00%
|
|
| US |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 4,023
|
3,978
|
$ 8,135
|
7,561
|
| US | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
1.00%
|
|
8.00%
|
|
| Net sales, change in %, cc |
1.00%
|
|
8.00%
|
|
| Innovative Medicines |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 9,188
|
9,326
|
$ 18,943
|
18,106
|
| Innovative Medicines | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(1.00%)
|
|
5.00%
|
|
| Net sales, change in %, cc |
1.00%
|
|
7.00%
|
|
| Innovative Medicines | Top 20 products [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 7,104
|
|
$ 14,494
|
|
| Innovative Medicines | Top 20 products [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
0.00%
|
|
6.00%
|
|
| Net sales, change in %, cc |
2.00%
|
|
8.00%
|
|
| Innovative Medicines | Rest of portfolio [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 2,084
|
|
$ 4,449
|
|
| Innovative Medicines | Rest of portfolio [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(6.00%)
|
|
1.00%
|
|
| Net sales, change in %, cc |
(4.00%)
|
|
4.00%
|
|
| Innovative Medicines | Oncology [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 3,548
|
3,606
|
$ 7,196
|
6,927
|
| Innovative Medicines | Oncology [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(2.00%)
|
|
4.00%
|
|
| Net sales, change in %, cc |
1.00%
|
|
6.00%
|
|
| Innovative Medicines | Oncology [member] | Tasigna [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 480
|
468
|
$ 967
|
902
|
| Innovative Medicines | Oncology [member] | Tasigna [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
3.00%
|
|
7.00%
|
|
| Net sales, change in %, cc |
5.00%
|
|
9.00%
|
|
| Innovative Medicines | Oncology [member] | Promacta/Revolade [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 422
|
349
|
$ 825
|
656
|
| Innovative Medicines | Oncology [member] | Promacta/Revolade [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
21.00%
|
|
26.00%
|
|
| Net sales, change in %, cc |
23.00%
|
|
28.00%
|
|
| Innovative Medicines | Oncology [member] | Tafinlar + Mekinist [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 371
|
340
|
$ 737
|
637
|
| Innovative Medicines | Oncology [member] | Tafinlar + Mekinist [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
9.00%
|
|
16.00%
|
|
| Net sales, change in %, cc |
12.00%
|
|
19.00%
|
|
| Innovative Medicines | Oncology [member] | Sandostatin [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 341
|
403
|
$ 715
|
795
|
| Innovative Medicines | Oncology [member] | Sandostatin [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(15.00%)
|
|
(10.00%)
|
|
| Net sales, change in %, cc |
(13.00%)
|
|
(8.00%)
|
|
| Innovative Medicines | Oncology [member] | Jakavi [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 310
|
284
|
$ 628
|
542
|
| Innovative Medicines | Oncology [member] | Jakavi [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
9.00%
|
|
16.00%
|
|
| Net sales, change in %, cc |
14.00%
|
|
20.00%
|
|
| Innovative Medicines | Oncology [member] | Gleevec/Glivec [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 288
|
323
|
$ 617
|
630
|
| Innovative Medicines | Oncology [member] | Gleevec/Glivec [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(11.00%)
|
|
(2.00%)
|
|
| Net sales, change in %, cc |
(8.00%)
|
|
0.00%
|
|
| Innovative Medicines | Oncology [member] | Afinitor/Votubia [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 266
|
401
|
$ 562
|
774
|
| Innovative Medicines | Oncology [member] | Afinitor/Votubia [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(34.00%)
|
|
(27.00%)
|
|
| Net sales, change in %, cc |
(33.00%)
|
|
(26.00%)
|
|
| Innovative Medicines | Oncology [member] | Exjade/Jadenu [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 163
|
253
|
$ 335
|
491
|
| Innovative Medicines | Oncology [member] | Exjade/Jadenu [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(36.00%)
|
|
(32.00%)
|
|
| Net sales, change in %, cc |
(35.00%)
|
|
(31.00%)
|
|
| Innovative Medicines | Oncology [member] | Votrient [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 162
|
193
|
$ 328
|
380
|
| Innovative Medicines | Oncology [member] | Votrient [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(16.00%)
|
|
(14.00%)
|
|
| Net sales, change in %, cc |
(14.00%)
|
|
(12.00%)
|
|
| Innovative Medicines | Oncology [member] | Kisqali [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 159
|
111
|
$ 320
|
202
|
| Innovative Medicines | Oncology [member] | Kisqali [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
43.00%
|
|
58.00%
|
|
| Net sales, change in %, cc |
49.00%
|
|
64.00%
|
|
| Innovative Medicines | Pharmaceutical [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 5,640
|
5,720
|
$ 11,747
|
11,179
|
| Innovative Medicines | Pharmaceutical [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(1.00%)
|
|
5.00%
|
|
| Net sales, change in %, cc |
1.00%
|
|
8.00%
|
|
| Innovative Medicines | Pharmaceutical [member] | Ophthalmology [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 937
|
1,174
|
$ 2,133
|
2,335
|
| Innovative Medicines | Pharmaceutical [member] | Ophthalmology [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(20.00%)
|
|
(9.00%)
|
|
| Net sales, change in %, cc |
(18.00%)
|
|
(7.00%)
|
|
| Innovative Medicines | Pharmaceutical [member] | Ophthalmology [member] | Lucentis [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 401
|
536
|
$ 888
|
1,069
|
| Innovative Medicines | Pharmaceutical [member] | Ophthalmology [member] | Lucentis [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(25.00%)
|
|
(17.00%)
|
|
| Net sales, change in %, cc |
(24.00%)
|
|
(15.00%)
|
|
| Innovative Medicines | Pharmaceutical [member] | Neuroscience [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 1,025
|
886
|
$ 2,045
|
1,683
|
| Innovative Medicines | Pharmaceutical [member] | Neuroscience [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
16.00%
|
|
22.00%
|
|
| Net sales, change in %, cc |
17.00%
|
|
23.00%
|
|
| Innovative Medicines | Pharmaceutical [member] | Neuroscience [member] | Gilenya [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 738
|
825
|
$ 1,510
|
1,591
|
| Innovative Medicines | Pharmaceutical [member] | Neuroscience [member] | Gilenya [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(11.00%)
|
|
(5.00%)
|
|
| Net sales, change in %, cc |
(9.00%)
|
|
(4.00%)
|
|
| Innovative Medicines | Pharmaceutical [member] | Neuroscience [member] | Zolgensma [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 205
|
15
|
$ 375
|
15
|
| Innovative Medicines | Pharmaceutical [member] | Neuroscience [member] | Top 20 products [member] | Zolgensma [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Reclassification of export sales |
|
|
44
|
|
| Innovative Medicines | Pharmaceutical [member] | Respiratory [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 444
|
461
|
$ 915
|
906
|
| Innovative Medicines | Pharmaceutical [member] | Respiratory [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(4.00%)
|
|
1.00%
|
|
| Net sales, change in %, cc |
0.00%
|
|
5.00%
|
|
| Innovative Medicines | Pharmaceutical [member] | Respiratory [member] | Xolair [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 289
|
290
|
$ 596
|
571
|
| Innovative Medicines | Pharmaceutical [member] | Respiratory [member] | Xolair [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
0.00%
|
|
4.00%
|
|
| Net sales, change in %, cc |
4.00%
|
|
8.00%
|
|
| Innovative Medicines | Pharmaceutical [member] | Cardiovascular, Renal and Metabolism [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 580
|
427
|
$ 1,150
|
790
|
| Innovative Medicines | Pharmaceutical [member] | Cardiovascular, Renal and Metabolism [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
36.00%
|
|
46.00%
|
|
| Net sales, change in %, cc |
38.00%
|
|
48.00%
|
|
| Innovative Medicines | Pharmaceutical [member] | Cardiovascular, Renal and Metabolism [member] | Entresto [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 580
|
421
|
$ 1,149
|
778
|
| Innovative Medicines | Pharmaceutical [member] | Cardiovascular, Renal and Metabolism [member] | Entresto [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
38.00%
|
|
48.00%
|
|
| Net sales, change in %, cc |
40.00%
|
|
50.00%
|
|
| Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 1,510
|
1,749
|
$ 3,217
|
3,500
|
| Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(14.00%)
|
|
(8.00%)
|
|
| Net sales, change in %, cc |
(9.00%)
|
|
(5.00%)
|
|
| Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Galvus Group [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 279
|
320
|
$ 617
|
635
|
| Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Galvus Group [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(13.00%)
|
|
(3.00%)
|
|
| Net sales, change in %, cc |
(8.00%)
|
|
1.00%
|
|
| Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Diovan Group [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 268
|
283
|
$ 542
|
544
|
| Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Diovan Group [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(5.00%)
|
|
0.00%
|
|
| Net sales, change in %, cc |
0.00%
|
|
4.00%
|
|
| Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Exforge Group [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 238
|
264
|
$ 496
|
531
|
| Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Exforge Group [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(10.00%)
|
|
(7.00%)
|
|
| Net sales, change in %, cc |
(5.00%)
|
|
(3.00%)
|
|
| Innovative Medicines | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 1,144
|
1,023
|
$ 2,287
|
1,965
|
| Innovative Medicines | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
12.00%
|
|
16.00%
|
|
| Net sales, change in %, cc |
13.00%
|
|
18.00%
|
|
| Innovative Medicines | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Cosentyx [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 944
|
858
|
$ 1,874
|
1,649
|
| Innovative Medicines | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Cosentyx [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
10.00%
|
|
14.00%
|
|
| Net sales, change in %, cc |
12.00%
|
|
15.00%
|
|
| Innovative Medicines | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Ilaris [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 200
|
165
|
$ 413
|
316
|
| Innovative Medicines | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Ilaris [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
21.00%
|
|
31.00%
|
|
| Net sales, change in %, cc |
23.00%
|
|
33.00%
|
|
| Innovative Medicines | US |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 3,515
|
$ 3,336
|
$ 7,057
|
$ 6,329
|
| Innovative Medicines | US | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
5.00%
|
|
12.00%
|
|
| Net sales, change in %, cc |
5.00%
|
|
12.00%
|
|
| Innovative Medicines | US | Top 20 products [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 2,772
|
|
$ 5,463
|
|
| Innovative Medicines | US | Top 20 products [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
5.00%
|
|
9.00%
|
|
| Innovative Medicines | US | Rest of portfolio [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 743
|
|
$ 1,594
|
|
| Innovative Medicines | US | Rest of portfolio [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
8.00%
|
|
21.00%
|
|
| Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Tasigna [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 221
|
|
$ 424
|
|
| Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Tasigna [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
8.00%
|
|
10.00%
|
|
| Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Promacta/Revolade [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 212
|
|
$ 399
|
|
| Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Promacta/Revolade [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
25.00%
|
|
25.00%
|
|
| Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Tafinlar + Mekinist [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 147
|
|
$ 279
|
|
| Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Tafinlar + Mekinist [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
20.00%
|
|
21.00%
|
|
| Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Sandostatin [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 200
|
|
$ 413
|
|
| Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Sandostatin [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(8.00%)
|
|
(5.00%)
|
|
| Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Gleevec/Glivec [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 70
|
|
$ 174
|
|
| Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Gleevec/Glivec [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(27.00%)
|
|
(1.00%)
|
|
| Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Afinitor/Votubia [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 163
|
|
$ 332
|
|
| Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Afinitor/Votubia [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(37.00%)
|
|
(33.00%)
|
|
| Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Exjade/Jadenu [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 34
|
|
$ 78
|
|
| Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Exjade/Jadenu [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(71.00%)
|
|
(66.00%)
|
|
| Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Votrient [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 72
|
|
$ 136
|
|
| Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Votrient [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(17.00%)
|
|
(21.00%)
|
|
| Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Kisqali [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 79
|
|
$ 153
|
|
| Innovative Medicines | US | Oncology [member] | Top 20 products [member] | Kisqali [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
36.00%
|
|
37.00%
|
|
| Innovative Medicines | US | Pharmaceutical [member] | Neuroscience [member] | Top 20 products [member] | Gilenya [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 416
|
|
$ 804
|
|
| Innovative Medicines | US | Pharmaceutical [member] | Neuroscience [member] | Top 20 products [member] | Gilenya [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(6.00%)
|
|
(3.00%)
|
|
| Innovative Medicines | US | Pharmaceutical [member] | Neuroscience [member] | Top 20 products [member] | Zolgensma [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 105
|
|
$ 231
|
|
| Innovative Medicines | US | Pharmaceutical [member] | Cardiovascular, Renal and Metabolism [member] | Entresto [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 308
|
|
$ 601
|
|
| Innovative Medicines | US | Pharmaceutical [member] | Cardiovascular, Renal and Metabolism [member] | Entresto [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
39.00%
|
|
43.00%
|
|
| Innovative Medicines | US | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Diovan Group [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 34
|
|
$ 60
|
|
| Innovative Medicines | US | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Diovan Group [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
21.00%
|
|
33.00%
|
|
| Innovative Medicines | US | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Exforge Group [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 2
|
|
$ 6
|
|
| Innovative Medicines | US | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Exforge Group [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(50.00%)
|
|
(14.00%)
|
|
| Innovative Medicines | US | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Top 20 products [member] | Cosentyx [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 614
|
|
$ 1,190
|
|
| Innovative Medicines | US | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Top 20 products [member] | Cosentyx [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
15.00%
|
|
18.00%
|
|
| Innovative Medicines | US | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Top 20 products [member] | Ilaris [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 95
|
|
$ 183
|
|
| Innovative Medicines | US | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Top 20 products [member] | Ilaris [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
23.00%
|
|
29.00%
|
|
| Innovative Medicines | Rest of the world [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 5,673
|
|
$ 11,886
|
|
| Innovative Medicines | Rest of the world [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(5.00%)
|
|
1.00%
|
|
| Net sales, change in %, cc |
(1.00%)
|
|
5.00%
|
|
| Innovative Medicines | Rest of the world [member] | Top 20 products [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 4,332
|
|
$ 9,031
|
|
| Innovative Medicines | Rest of the world [member] | Top 20 products [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(3.00%)
|
|
4.00%
|
|
| Net sales, change in %, cc |
1.00%
|
|
8.00%
|
|
| Innovative Medicines | Rest of the world [member] | Rest of portfolio [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 1,341
|
|
$ 2,855
|
|
| Innovative Medicines | Rest of the world [member] | Rest of portfolio [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(13.00%)
|
|
(7.00%)
|
|
| Net sales, change in %, cc |
(9.00%)
|
|
(4.00%)
|
|
| Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Tasigna [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 259
|
|
$ 543
|
|
| Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Tasigna [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(2.00%)
|
|
5.00%
|
|
| Net sales, change in %, cc |
2.00%
|
|
9.00%
|
|
| Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Promacta/Revolade [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 210
|
|
$ 426
|
|
| Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Promacta/Revolade [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
17.00%
|
|
26.00%
|
|
| Net sales, change in %, cc |
22.00%
|
|
30.00%
|
|
| Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Tafinlar + Mekinist [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 224
|
|
$ 458
|
|
| Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Tafinlar + Mekinist [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
3.00%
|
|
13.00%
|
|
| Net sales, change in %, cc |
8.00%
|
|
17.00%
|
|
| Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Sandostatin [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 141
|
|
$ 302
|
|
| Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Sandostatin [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(24.00%)
|
|
(17.00%)
|
|
| Net sales, change in %, cc |
(19.00%)
|
|
(12.00%)
|
|
| Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Jakavi [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 310
|
|
$ 628
|
|
| Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Jakavi [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
9.00%
|
|
16.00%
|
|
| Net sales, change in %, cc |
14.00%
|
|
20.00%
|
|
| Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Gleevec/Glivec [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 218
|
|
$ 443
|
|
| Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Gleevec/Glivec [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(4.00%)
|
|
(3.00%)
|
|
| Net sales, change in %, cc |
0.00%
|
|
1.00%
|
|
| Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Afinitor/Votubia [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 103
|
|
$ 230
|
|
| Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Afinitor/Votubia [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(27.00%)
|
|
(18.00%)
|
|
| Net sales, change in %, cc |
(24.00%)
|
|
(15.00%)
|
|
| Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Exjade/Jadenu [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 129
|
|
$ 257
|
|
| Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Exjade/Jadenu [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(4.00%)
|
|
(1.00%)
|
|
| Net sales, change in %, cc |
(3.00%)
|
|
1.00%
|
|
| Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Votrient [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 90
|
|
$ 192
|
|
| Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Votrient [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(15.00%)
|
|
(8.00%)
|
|
| Net sales, change in %, cc |
(12.00%)
|
|
(5.00%)
|
|
| Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Kisqali [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 80
|
|
$ 167
|
|
| Innovative Medicines | Rest of the world [member] | Oncology [member] | Top 20 products [member] | Kisqali [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
51.00%
|
|
86.00%
|
|
| Net sales, change in %, cc |
63.00%
|
|
97.00%
|
|
| Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Ophthalmology [member] | Top 20 products [member] | Lucentis [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 401
|
|
$ 888
|
|
| Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Ophthalmology [member] | Top 20 products [member] | Lucentis [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(25.00%)
|
|
(17.00%)
|
|
| Net sales, change in %, cc |
(24.00%)
|
|
(15.00%)
|
|
| Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Neuroscience [member] | Top 20 products [member] | Gilenya [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 322
|
|
$ 706
|
|
| Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Neuroscience [member] | Top 20 products [member] | Gilenya [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(16.00%)
|
|
(7.00%)
|
|
| Net sales, change in %, cc |
(13.00%)
|
|
(4.00%)
|
|
| Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Neuroscience [member] | Top 20 products [member] | Zolgensma [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 100
|
|
$ 144
|
|
| Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Respiratory [member] | Top 20 products [member] | Xolair [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 289
|
|
$ 596
|
|
| Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Respiratory [member] | Top 20 products [member] | Xolair [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
0.00%
|
|
4.00%
|
|
| Net sales, change in %, cc |
4.00%
|
|
8.00%
|
|
| Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Cardiovascular, Renal and Metabolism [member] | Entresto [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 272
|
|
$ 548
|
|
| Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Cardiovascular, Renal and Metabolism [member] | Entresto [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
36.00%
|
|
53.00%
|
|
| Net sales, change in %, cc |
41.00%
|
|
58.00%
|
|
| Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Galvus Group [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 279
|
|
$ 617
|
|
| Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Galvus Group [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(13.00%)
|
|
(3.00%)
|
|
| Net sales, change in %, cc |
(8.00%)
|
|
1.00%
|
|
| Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Diovan Group [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 234
|
|
$ 482
|
|
| Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Diovan Group [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(8.00%)
|
|
(3.00%)
|
|
| Net sales, change in %, cc |
(2.00%)
|
|
2.00%
|
|
| Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Exforge Group [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 236
|
|
$ 490
|
|
| Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Established Medicines [member] | Top 20 products [member] | Exforge Group [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
(9.00%)
|
|
(6.00%)
|
|
| Net sales, change in %, cc |
(5.00%)
|
|
(3.00%)
|
|
| Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Top 20 products [member] | Cosentyx [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 330
|
|
$ 684
|
|
| Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Top 20 products [member] | Cosentyx [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
2.00%
|
|
7.00%
|
|
| Net sales, change in %, cc |
6.00%
|
|
11.00%
|
|
| Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Top 20 products [member] | Ilaris [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales to third parties from continuing operations |
$ 105
|
|
$ 230
|
|
| Innovative Medicines | Rest of the world [member] | Pharmaceutical [member] | Immunology, Hepatology and Dermatology [member] | Top 20 products [member] | Ilaris [member] | Change over period [member] |
|
|
|
|
| Disclosure of operating segments [line items] |
|
|
|
|
| Net sales, change in % |
19.00%
|
|
32.00%
|
|
| Net sales, change in %, cc |
22.00%
|
|
36.00%
|
|